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Aims Although previous reports suggest that an elevated endogenous erythropoietin (EPO) level is associated with worse
clinical outcomes in chronic heart failure (HF) patients, the prognostic implication of EPO in patients with acute
decompensated HF (ADHF) and underlying mechanisms of the high EPO level in severe HF patients who have a poor
prognosis remain unclear.
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Methods
and results
We examined 539 consecutive ADHF patients with EPO measurement on admission from our registry. During a
median follow-up period of 329 days, a higher EPO level on admission was independently associated with worse
clinical outcomes [hazard ratio (HR) 1.25, 95% confidence interval (CI) 1.06–1.48, P = 0.008], and haemoglobin
level was the strongest determinant of EPO level (P < 0.001), whereas estimated glomerular filtration rate (eGFR)
was not significant in multivariate regression analysis. In the anaemic subgroup of 318 patients, a higher EPO level
than expected on the basis of their haemoglobin level was related to increased adverse events (HR 1.63, 95% CI
1.05–2.49, P = 0.028). Moreover, estimated plasma volume excess rate was positively associated with EPO level (P
= 0.003), and anaemic patients with a higher than expected EPO level tended to have a higher estimated plasma
volume excess rate and plasma lactate level, and lower systemic oxygen saturation level with the preservation of the
reticulocyte production index than those with a lower than expected EPO level.
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Conclusion A high EPO level predicts long-term worse clinical outcomes in ADHF patients, independent of anaemia and impaired
renal function. Anaemia and hypoxia due to severe congestion may synergistically contribute to a high EPO level in
high-risk HF patients.
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Introduction
Despite dramatic advances in diagnosis and treatment, the prog-
nosis of heart failure (HF) remains poor. Indeed, the Framingham
Heart Study indicated that HF is still highly fatal, and in subjects
who were diagnosed with HF in the 1990s, more than half of
them died within 5 years, and the mortality had declined by only
one-third from that in the 1950s.1 Failure to improve the mortality
of HF patients has prompted investigators to seek novel mecha-
nisms related to prognostic determinants of HF.
Multiple co-morbid conditions are frequently observed in
patients with HF. Among them, anaemia and renal insufficiency
were reported to be strong prognostic determinants of HF
patients.2,3 Furthermore, the interaction between these condi-
tions has been suggested to form a vicious cycle, termed the
‘cardio-renal–anaemia syndrome’, where HF may cause progres-
sive renal dysfunction and both may lead to anaemia, which in turn
can worsen HF and renal insufficiency.4
Endogenous erythropoietin (EPO) is mostly produced in the
kidney by stimulation such as hypoxia, which is the fundamental
physiological stimulus for EPO production through a rapid increase
in the number of renal EPO-producing cells.5 Impairment of EPO
production is a major cause of anaemia in HF patients with renal
insufficiency; therefore, EPO has been expected to be reduced
in the cardio-renal–anaemia syndrome. In contrast, several pre-
vious studies revealed that an elevated EPO level was frequently
observed and was associated with impaired survival, independent
of anaemia and renal function, in chronic HF patients.6–10 Of
them, Belonje et al. reported that the EPO measurement was
useful for future risk stratification in a large cohort of chronic HF
patients, and that a higher than expected EPO level based on the
prediction by haemoglobin level in the anaemic subgroup could
predict worse clinical outcomes.10 These results indicate that EPO
plays an important role in identifying chronic HF patients at risk
for future adverse events.
However, the prognostic implication of EPO in patients with
acute decompensated HF (ADHF) and the underlying mechanisms
of the high EPO level in patients with severe HF who have a poor
prognosis remain unclear, despite several mechanisms having been
hypothesized.9–12
Thus, the aim of the present study was to investigate whether the
high EPO level in the decompensated phase of HF was associated
with worse clinical outcomes, and to explore the pathophysio-
logical mechanisms of a high EPO level in high-risk patients in a
relatively large ADHF cohort.
Methods
Study design
Data from the NaDEF (National cerebral and cardiovascular center
acute DEcompensated heart Failure) registry, which were obtained
between January 2013 and March 2015, were retrospectively anal-
ysed. The NaDEF registry is a single-centre, observational, ongoing,
prospective cohort that includes all patients requiring hospitalization
to our institution from January 2013 for the first time with a diagno-
sis of ADHF by at least two experienced cardiologists according to ..
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Consecutive patients with ADHF registered to NaDEF
Jan 2013 – Mar 2015 (n = 651)
Total population
(n = 539)
Anaemic population
(n=318)
Haemoglobin > 13 g/dL (men), >12 g/dl (women)
(n=221)
Excluded:
Excluded:
Acute coronary syndrome (n=34)
Haemodialysis (n=14)
eGFR < 10 mL/min (n=23)
No EPO measurement (n=59)
Figure 1 Study population. ADHF, acute decompensated heart
failure; eGFR, estimated glomerular filtration rate; EPO, erythro-
poietin.
the Framingham ADHF criteria,13 and follow-up was performed at 3,
6, 12, and 24 months after discharge by direct contact with patients
or patients’ physicians at the hospital or outpatient clinic, telephone
interview of patients, or, if deceased, of family members, and by mail, by
dedicated co-ordinators and investigators. In this study, because patient
information was anonymized and de-identified prior to analyses, writ-
ten informed consent was not obtained from each patient. However,
we publicized the study by posting a summary of the protocol (with an
easily understood description) on the website of the National Cere-
bral and Cardiovascular Center; the notice clearly informed patients of
their right to refuse enrolment. These procedures for informed con-
sent and enrolment were in accordance with the detailed regulations
regarding informed consent described in the guidelines, and this study,
including the procedure for enrolment, has been approved by the Insti-
tutional Review Board of the National Cerebral and Cardiovascular
Center (M22-025), and registered under the Japanese UMIN Clinical
Trials Registration (UMIN000017024).
Study population
From the 651 patients enrolled in the NaDEF registry, those with
acute coronary syndrome or without measurement of EPO were
excluded from this study. To minimize errors influencing the level of
endogenous EPO, patients with estimated glomerular filtration rate
(eGFR) <10mL/min or on maintenance haemodialysis on admission
were also excluded. Finally, 539 patients were examined (Figure 1).
Renal function and anaemia
The eGFR was determined using the abbreviated Modification of Diet
in Renal Disease equation: eGFR=186.3× (creatinine/88.4)1.154 ×
(age)–0.203 (×0.742 if female).14 Anaemia was defined according to the
World Health Organization criteria as a haemoglobin level <13.0 g/dL
in men and <12.0 g/dL in women.
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Table 1 Baseline characteristics of the total population
Variable All patients EPO quartile P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 2 3 4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number 539 134 135 135 135 –
EPO range, U/L – <23.0 23.0–38.3 38.4–78.9 ≥79.0 –
Age, years 75.8±11.8 72.0±13.1 76.8± 10.6 76.6±12.2 77.7±10.2* <0.001
Male sex, n (%) 320 (59) 82 (61) 84 (62) 74 (55) 80 (59) 0.61
NYHA III or IV, n (%) 442 (89) 109 (89) 112 (89) 106 (86) 116 (90) 0.54
Past history
AF, n (%) 278 (52) 58 (43) 67 (50) 69 (51) 84 (62) 0.018
Hypertension, n (%) 378 (70) 89 (66) 101 (75) 95 (70) 93 (69) 0.43
Diabetes mellitus, n (%) 190 (35) 46 (35) 48 (36) 45 (33) 51 (38) 0.87
Systolic BP, mmHg 139.3± 32.4 140.2± 34.0 143.8± 30.8 139.9± 31.9 133.2± 32.1 0.057
Heart rate, b.p.m. 92.4± 28.6 95.6± 29.4 88.0± 26.5 94.2± 29.8 92.0± 28.3 0.148
SpO2, % 94.1± 5.1 94.5± 4.1 93.8± 4.7 94.7± 5.0 93.6± 6.3 0.20
LVEF, % 38.2±17.1 37.5±17.9 38.0± 16.4 39.0±16.1 38.5±18.2 0.92
Estimated PV excess rate, % 9.3± 11.8 5.3±11.1 7.9± 10.6 10.3±11.2 13.8±12.9 <0.001
Aetiology
ICM, n (%) 121 (23) 26 (20) 33 (24) 30 (22) 32 (24) 0.30
NICM, n (%) 187 (35) 53 (40) 42 (31) 46 (34) 46 (34)
Valvular disease, n (%) 134 (25) 28 (21) 36 (27) 34 (25) 36 (27)
Other, n (%) 93 (17) 24 (18) 24 (18) 25 (19) 20 (15)
Oral medications at admission
ACE inhibitors/ARBs, n (%) 280 (52) 63 (47) 77 (57) 68 (50) 72 (53) 0.40
Beta-blockers, n (%) 284 (53) 59 (44) 82 (61) 64 (47) 79 (59) 0.012
Diuretics, n (%) 302 (56) 63 (47) 75 (56) 75 (56) 89 (66) 0.020
Spironolactone, n (%) 110 (20) 33 (25) 22 (16) 22 (16) 33 (24) 0.12
Continuous variables are presented as mean± SD.
Categorical variables are presented as number of patients (%).
BP, blood pressure; EPO, erythropoietin; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic cardiomyopathy; PV, plasma volume; SpO2, oxygen saturation by pulse oximetry.
*P< 0.001 vs. quartile 1.
Blood sampling and erythropoietin
measurement
Venous blood samples for routine laboratory measurements and
EPO were measured on admission. Blood samples were collected
in pyrogen-free tubes containing EDTA (Becton Dickinson, San Jose,
CA, USA) and were immediately centrifuged at 2000 g for 30min at
4 ∘C. Platelet-poor serum was separated and stored at −80 ∘C until
analysis. Serum EPO level was measured with a Recombigen EPO Kit
(LSI Medience Corp., Tokyo, Japan). This assay consists of an anti-EPO
rabbit capture antibody, iodine-labelled recombinant human EPO, and
secondary antibody (serum anti-rabbit IgG). The amount of serum
EPO was quantified by radioimmunoassay. The analytical parameters
for the assay were intra-assay coefficient of variation (CV), 2.6–4.0%;
interassay CV, 4.7–5.3%; limit of detection, 4.0 mIU/mL; and linearity,
4.0–200 mIU/mL.
Erythropoietin responsiveness
We used a similar approach to those used in previous studies to
determine the response of endogenous EPO to the haemoglobin
level in anaemic patients.10,15,16 To avoid interference with EPO
production or EPO activity due to renal function and HF, a sample of
35 anaemic patients in our outpatient clinic cohort (different from our
ADHF cohort) without renal disease or HF (previous history of HF,
symptoms or signs of HF, LVEF <50%, or moderate to severe valvular .
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. heart disease) was obtained to construct a regression equation as a
reference. The equation, 9.626 – (0.503× haemoglobin)= log EPO,
was used to calculate the predicted EPO value for a given haemoglobin
level. The observed log EPO level in anaemic patients in the present
study was divided by the predicted log EPO level to obtain the
observed/predicted (O/P) ratio. The mean O/P ratio for the reference
subjects was 1.001 [95% confidence interval (CI), 0.938–1.064]. An
O/P ratio <0.938 indicates a lower than expected EPO production.
An O/P ratio >1.064 implies a higher than expected EPO production.
Moreover, the erythropoietic response was also determined by calcu-
lating the reticulocyte production index (RPI), a standard measure of
reticulocyte production that corrects for both the degree of anaemia
and the early release of reticulocytes from bone marrow in anaemic
patients.17
RPI was calculated using the following equation:
RPI= reticulocytes (%)× [observed haematocrit/normal haemat-
ocrit (45 for men, 40 for women)]× (1/maturation factor defined by
sex and observed haematocrit).
Iron deficiency was defined as a ferritin level <100 μg /L or between
100 and 299 μg/L, if transferrin saturation (TSAT) was <20%, based on
the major previous clinical trial.18
Plasma volume estimation
To assess the influence of congestion and dilutional anaemia on EPO
production on admission (decompensated phase) in anaemic ADHF
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Table 2 Laboratory data and initial treatments of the total population
Variable All patients EPO quartile P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1 2 3 4
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Number 539 134 135 135 135 –
EPO range, U/L – <23.0 23.0–38.3 38.4–78.9 ≥79.0 –
Laboratory data
EPO, U/L 38 (23–79) 19 (16–21) 30 (26–34) 51 (43–63) 151 (103–277)* <0.001
Log EPO, U/L 3.88± 0.99 2.89± 0.19 3.39± 0.15* 3.96± 0.22* 5.27± 0.79* <0.001
Haemoglobin, g/dL 12.0± 2.1 12.9± 2.0 12.6±1.7 11.7±1.9* 10.9± 2.1* <0.001
Platelets, ×104/𝜇L 16.6± 5.8 17.7± 6.1 16.0± 5.2 16.6± 5.8 16.1± 5.9 0.077
Fe, μg/dL 50 (33–70) 52 (34–80) 53 (35–74) 50 (36–68) 45 (28–63) 0.22
Ferritin, μg/L 109 (58–225) 140 (76–262) 117 (65–222) 97 (59–206) 90 (38–213) 0.31
TSAT, % 18.4 (12.3–26.2) 19.6 (13.4–28.9) 19.0 (12.8–29.5) 18.7 (13.5–25.8) 16.8 (9.1–24.5) 0.18
Iron deficiency, n (%) 320 (59) 71 (53) 81 (60) 84 (62) 84 (62) 0.35
eGFR, mL/min/1.73m2 47.1 (30.9–60.1) 52.6 (34.9–67.6) 49.5 (36.0–60.7) 45.6 (33.7–54.0) 41.0 (26.2–54.0)* <0.001
Sodium, mEq/L 139.6± 4.4 139.2± 4.1 140.0± 3.9 139.5± 4.8 139.5± 4.6 0.53
BNP, pg/mL 594 (308–1077) 479 (182–804) 541 (276–976) 606 (332–1233) 743 (429–1366)* <0.001
hs TnT, ng/mL 0.04 (0.02–0.07) 0.03 (0.02–0.05) 0.04 (0.02–0.07) 0.04 (0.02–0.07) 0.05 (0.03–0.07) 0.50
CRP, mg/dL 0.42 (0.14–1.22) 0.36 (0.12–1.19) 0.28 (0.10–0.88) 0.44 (0.13–1.23) 0.70 (0.25–1.88) 0.48
Renin activity, ng/mL/h 1.7 (0.6–6.6) 2.2 (0.6–8.3) 1.6 (0.6–4.7) 1.5 (0.5–4.3) 1.8 (0.6–9.6) 0.003
Aldosterone, ng/dL 9.5 (5.8–24.2) 10.4 (6.8–20.1) 7.9 (5.6–18.3) 10.5 (6.1–21.7) 9.2 (4.8–43.5) 0.001
Lactate, mg/dL 13.5 (10.0–18.0) 14.0 (10.1–18.7) 14.0 (10.4–18.0) 13.5 (10.3–17.1) 12.9 (9.0–20.9) 0.75
Urinary albumin, mg/g creatinine 59 (23–175) 51 (15–151) 54 (23–117) 65 (22–216) 79 (35–260) 0.24
Urine NAG, U/L 8.4 (4.7–14.7) 9.2 (4.8–15.4) 6.9 (4.6–11.5) 9.3 (5.7–16.4) 8.4 (3.7–13.7) 0.083
Urine 𝛽2-MG, μg/L 293 (97–1353) 317 (102–1433) 304 (129–1360) 275 (82–1215) 272 (77–1630) 0.63
Intravenous treatments
Diuretics, n (%) 398 (74) 100 (75) 91 (68) 100 (75) 107 (79) 0.20
Vasodilators, n (%) 319 (60) 77 (58) 78 (59) 83 (61) 81 (60) 0.94
Inotropes, n (%) 79 (15) 23 (17) 12 (9) 17 (13) 27 (20) 0.050
Continuous variables are presented as mean± SD if normally distributed, and median (interquartile range) if not normally distributed.
Categorical variables are presented as number of patients (%).
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; Fe, serum iron; hs TnT, high-sensitive troponin T; MG, microglobulin; NAG,
N-acetyl-𝛽-D-glucosaminidase; TSAT, transferrin saturation.
*P< 0.001 vs. quartile 1.
patients, we estimated plasma volume (PV) excess on admission. Total
blood volume was estimated from their ideal weight as previously
reported (ideal body weight method).19 Briefly, from the deviation in
real body weight from ideal body weight, which was normalized for
height, the ratio of total blood volume to body weight was determined
for each patient. Then, estimated PV was calculated using the following
equation:
Estimated PV= body weight× (designated total blood volume/body
weight ratio)× (1 – haematocrit).
The estimated PV excess rate, defined as the ratio of (admis-
sion – pre-discharge) estimated PV to the estimated PV pre-discharge,
was then calculated in each patient. This method was validated by a
study that analysed relatively large healthy volunteers who underwent
scintigraphy with radiolabelled albumin,19 and was used in ADHF
patients.20
Study endpoints
The study endpoint was all-cause death and worsening HF, which was
defined as worsening of symptoms and signs of HF requiring intensifica-
tion of intravenous therapy or initiation of mechanical support during
hospitalization, as used in major AHF clinical trials,21,22 or readmission
due to HF after discharge. .
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Results are presented as mean± SD when normally distributed, and as
median and interquartile range (IQR) when non-normally distributed.
Comparisons of differences between groups were made by analysis of
variance (ANOVA) with Bonferroni’s post-hoc testing for continuous
variable, and by 𝜒2 test or Fisher’s exact test for dichotomous vari-
ables, when appropriate. For the total population, multivariate linear
regression analysis was performed based on the variables achiev-
ing P< 0.10 on univariate linear regression analysis to explore the
strongest independent determinant of log EPO level. For the total pop-
ulation, Kaplan–Meier survival plots were constructed by dividing the
EPO level at baseline into quartiles to study the influence of EPO level
on all-cause mortality and worsening HF. For the anaemic population,
Kaplan–Meier plots were constructed for the different groups of O/P
ratio of EPO levels on admission, and log-rank testing was performed.
The association between parameters and the composite of all-cause
mortality and worsening HF was assessed by Cox proportional hazards
regression. Univariate factors that had a value of P< 0.10 were iden-
tified. Finally, these factors were entered into the multivariate model
to assess the impact of EPO level on admission on the composite of
all-cause mortality and worsening HF. Moreover, stepwise selection
with a P-value of 0.10 for backward elimination was used to select
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Figure 2 Kaplan–Meier analyses of clinical outcomes categorized by erythropoietin (EPO) level. (A) Composite of all-cause death and
worsening heart failure. (B) All-cause death. (C) Worsening heart failure. Q, quartile.
the best predictive model in the total population. Adding to the main
effect, the interaction between log EPO and other covariates was
also examined in the total population. All tests were two tailed, and
a value of P< 0.05 was considered statistically significant. All analyses
were performed with SPSS® for Windows version 21.0 (IBM, Corp.,
Armonk, NY, USA) and STATA® 13 (Stata Corp, College Station,
TX, USA).
Results
Patient characteristics
The clinical characteristics of the total 539 patients are shown in
Tables 1 and 2. Although patients with higher EPO quartiles were .
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. older and had lower systolic blood pressure, haemoglobin, and
eGFR levels, and higher plasma BNP level compared with those
with lower EPO quartiles, there were no significant differences
in sex, NYHA functional class, LVEF, aetiology of HF, oxygen
saturation level by pulse oximetry (SpO2), estimated PV excess
rate, platelet count, iron status, urinary albumin level, renal tubular
injury markers, plasma lactate level, and intravenous treatment
among the quartiles. The median EPO level on admission was 38
U/L.
Erythropoietin level and clinical outcome
During a median follow-up period of 329 days (IQR 110–541
days), adverse events (composite of death and worsening HF,
© 2016 The Authors
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Table 3 Cox proportional hazards model for composite of death and worsening heart failure in the total population
Variable Univariate Multivariate (significant
covariates in univariate analyses)
Multivariate (stepwise
selection)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, 5 years 1.12 (1.04–1.21) 0.003 1.05 (0.96–1.16) 0.25 Not selected –
Systolic BP, 10mmHg 0.94 (0.89–0.99) 0.018 0.98 (0.92–1.04) 0.44 Not selected –
BNP, 100 pg/mL 1.03 (1.01–1.04) 0.002 1.02 (1.00–1.04) 0.048 1.02 (1.00–1.04) 0.066
eGFR, 10mL/min/1.73m2 0.81 (0.74–0.89) <0.001 0.85 (0.76–0.94) 0.002 0.82 (0.74–0.90) <0.001
Haemoglobin, 1 g/dL 0.88 (0.81–0.95) 0.001 0.98 (0.89–1.09) 0.74 Not selected –
Log EPO, 1 U/L 1.43 (1.24 –1.64) <0.001 1.21 (1.02 –1.45) 0.032 1.25 (1.06–1.48) 0.008
SpO2, 1 % 0.98 (0.95–1.01) 0.157 Not selected – Not selected –
Sodium, 1mEq/L 0.96 (0.92–0.99) 0.029 0.97 (0.93–1.01) 0.147 Not selected –
Male sex 1.19 (0.85–1.68) 0.31 Not selected – Not selected –
Lactate, 1mg/dL 1.00 (0.98–1.02) 0.68 Not selected – Not selected –
Urinary albumin, 100mg/g creatinine 1.00 (0.97–1.03) 0.80 Not selected – Not selected –
Platelets, 104/𝜇L 0.97 (0.95–1.01) 0.17 Not selected – Not selected –
Estimated PV excess rate, 1% 1.00 (0.98–1.01) 0.89 Not selected – Not selected –
BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; HR, hazard ratio; PV, plasma volume; SpO2, oxygen saturation by
pulse oximetry.
death, and worsening HF) occurred in 166 (30.8%), 50 (9.3%),
and 142 (26.3%) study patients, respectively. Kaplan–Meier analy-
ses revealed that a higher EPO level on admission was significantly
associated with worse clinical outcomes including the composite
of death and worsening HF, death, and worsening HF (log-rank;
P< 0.001, P< 0.001, and P< 0.001, respectively; Figure 2). In the
multivariate Cox proportional hazards model, a higher log EPO
level and lower eGFR were significantly associated with the com-
posite of death and worsening HF among variables including higher
age and plasma BNP level, and lower systolic BP, haemoglobin, and
serum sodium levels (Table 3). Furthermore, in adjusted Cox mod-
els, the risk of the composite of death and worsening HF in the
highest quartile was almost 1.7-fold higher than that in the low-
est quartile of log EPO levels [hazard ratio (HR) 1.68, 95% CI
1.03–2.73; P for trend= 0.011]. Although a significant interaction
between log EPO and age was identified (P= 0.004), there were no
interactions between log EPO and other variables on outcomes.
The risk was stratified by the mean age of 75 years (HR 1.49, 95%
CI 1.10–2.02, P= 0.004, <75 years; HR 1.05, 95% CI 0.83–1.32,
P= 0.68, ≥75 years).
Erythropoietin responsiveness in the
anaemic subgroup
In multivariate linear regression analysis, haemoglobin level was the
strongest determinant of log EPO level among eGFR, plasma BNP
level, systolic BP, estimated PV excess rate, and iron status (Fe,
ferritin, TSAT) (Table 4). Then the subanalyses in the ‘anaemic’
population were performed to explore the pathophysiological
mechanisms of the high EPO level. The median EPO level in the
anaemic subgroup of 318 patients was 49 U/L. The subgroup was
divided into three groups based on the O/P ratio. As shown in
Tables 5 and 6, anaemic patients with a higher EPO level than .
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.. Table 4 Linear regression analyses of log
erythropoietin level in the total population
Variable Univariate Multivariate
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
𝜷
coefficient
P-
value
𝜷
coefficient
P-
value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 0.14 <0.001 −0.004 0.93
BNP 0.23 <0.001 0.23 <0.001
eGFR −0.23 <0.001 −0.07 0.11
Haemoglobin −0.40 <0.001 −0.35 <0.001
SpO2 −0.03 0.52 Not selected –
Estimated PV excess rate 0.29 <0.001 0.13 0.004
Systolic BP −0.13 0.003 −0.02 0.68
Platelets −0.09 0.041 −0.03 0.49
Urinary albumin 0.04 0.41 Not selected –
Fe −0.07 0.067 0.25 0.004
Ferritin 0.12 0.006 0.13 0.002
TSAT −0.08 0.062 −0.27 0.003
BP, blood pressure; eGFR, estimated glomerular filtration rate; Fe, serum iron;
PV, plasma volume; SpO2, oxygen saturation by pulse oximetry; TSAT, transferrin
saturation.
expected had higher haemoglobin, serum sodium, and plasma BNP
levels compared with those with a lower EPO level than expected.
Moreover, anaemic patients with a higher EPO level than expected
tended to have a higher estimated PV excess rate and plasma
lactate level, and a lower SpO2 level on admission, which might
reflect severe congestion on admission compared with those with
a lower EPO level than expected (Tables 5 and 6). Regarding
EPO responsiveness, anaemic patients with a higher EPO level
than expected had a significantly higher RPI, which could reflect
the preserved reticulocyte-producing potential of bone marrow in
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Table 5 Baseline characteristics of anaemic patients
Variable All anaemic
patients
(n= 318)
Lower EPO level
than expected
(n= 149)
EPO level
as expected
(n= 71)
Higher EPO
level than
expected (n= 98)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 79.2± 9.7 80.1± 8.9 80.1±10.0 77.2±10.5 0.056
Male sex, n (%) 186 (58) 78 (52) 43 (61) 65 (66) 0.084
NYHA III or IV, n (%) 261 (82) 126 (85) 56 (79) 79 (81) 0.53
Past history
AF, n (%) 170 (53) 77 (52) 40 (56) 53 (54) 0.80
Hypertension, n (%) 230 (72) 109 (73) 51 (72) 70 (71) 0.95
Diabetes mellitus, n (%) 122 (38) 64 (43) 24 (34) 34 (35) 0.30
Systolic BP, mmHg 138.4± 30.1 139.9± 28.9 141.0± 32.8 134.1± 29.9 0.24
Heart rate, b.p.m. 87.7± 26.8 84.8± 25.8 87.4± 24.5 92.2± 29.6 0.107
SpO2, % 94.3± 5.3 94.6± 4.8 94.9± 4.1 93.5± 6.5 0.161
LVEF, % 41.3±16.9 43.6± 16.9 40.7± 16.9 38.4±16.8 0.089
Estimated PV excess rate, % 11.6±11.2 10.6±10.8 12.5±11.0 12.4± 12.0 0.37
Aetiology
ICM, n (%) 78 (25) 34 (23) 24 (34) 20 (34) 0.107
NICM, n (%) 86 (27) 36 (24) 15 (21) 35 (21)
Valvular disease, n (%) 96 (30) 51 (34) 22 (31) 23 (31)
Other, n (%) 58 (18) 28 (19) 10 (14) 20 (14)
Oral medications at admission
ACE inhibitor/ARBs, n (%) 173 (54) 85 (57) 35 (49) 53 (54) 0.56
Beta-blockers, n (%) 165 (52) 75 (50) 35 (49) 55 (56) 0.59
Diuretics, n (%) 195 (61) 94 (63) 32 (45) 69 (70) 0.003
Spironolactone, n (%) 65 (20) 29 (19) 15 (21) 21 (21) 0.92
Continuous variables are presented as mean± SD.
Categorical variables are presented as number of patients (%).
BP, blood pressure; EPO, erythropoietin; ICM, ischaemic cardiomyopathy; NICM, non-ischaemic cardiomyopathy; PV, plasma volume; SpO2, oxygen saturation by pulse oximetry.
*P< 0.01 vs. lower EPO level than expected.
response to circulating EPO, compared with those with a lower
EPO level than expected (Tables 5 and 6). However, age, sex,
systolic blood pressure, eGFR, C-reactive protein, plasma renin
activity, aldosterone levels, platelet count, iron status, urinary
albumin level, and renal tubular injury markers were comparable
among the groups. In the anaemic population, during a median
follow-up period of 330 days (IQR 119–554 days), Kaplan–Meier
analyses demonstrated that a higher EPO level than expected was
associated with worse clinical outcomes, especially with worsening
HF (Figure 3). Furthermore, multivariate Cox proportional hazard
modelling revealed that a higher than expected EPO level was
independently associated with worse clinical outcomes (composite
of death and worsening HF) among other confounders including
plasma BNP and haemoglobin levels, eGFR, and systolic blood
pressure (Table 7).
Discussion
The present findings indicate that a high circulating EPO level on
admission was significantly associated with future adverse events
in patients with ADHF. We also found that a higher than expected
EPO level was independently associated with worse clinical out-
comes in the anaemic ADHF subgroup. Importantly, anaemic
ADHF patients with a higher than expected EPO level had higher ..
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.. bone marrow reticulocyte production compared with those with
a lower than expected EPO level, indicating that blunted reticu-
locyte responsiveness to EPO of bone marrow might not con-
tribute to a high systemic EPO level. Furthermore, patients with
a higher than expected EPO level tended to have a higher esti-
mated PV excess rate and plasma lactate level, with a lower
SpO2 level compared with those with a lower than expected EPO
level, suggesting that the high EPO level might be partly caused
by severe congestion and hypoxia during the decompensated
phase.
Previous studies have demonstrated that an elevated EPO level
was an independent determinant of worse clinical outcomes in
chronic HF and the compensated phase of hospitalized HF.6–8,10,15
In the present study, we confirmed these findings in a relatively
larger cohort of ADHF patients in whom EPO was measured on
admission. In addition, our ADHF cohort had a higher prevalence
of anaemic patients and worse clinical outcomes compared with
the previous cohort of compensated hospitalized patients with
HF which included acute and chronic HF (59.0% vs. 22.3%).10
Interestingly, 31% of anaemic ADHF patients had a higher than
expected EPO level, given their haemoglobin value, and this
rate was also higher in the ADHF cohort than in compensated
HF patients (only 9% of anaemic patients).10 Therefore, our
cohort was considered to be appropriate for exploring the
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Table 6 Laboratory data and initial treatments of anaemic patients
Variable All anaemic
patients
(n= 318)
Lower EPO
level than
expected (n= 149)
EPO level
as expected
(n= 71)
Higher EPO
level than
expected (n= 98)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Laboratory data
EPO, U/L 49 (29–108) 31 (21–44) 56 (37–98) 141 (77–308)* <0.001
Log EPO, U/L 4.13± 1.04 3.49± 0.63 4.17± 0.71* 5.07± 1.02* <0.001
O/P ratio 0.97± 0.23 0.79± 0.11 0.99± 0.04* 1.27± 0.19* <0.001
Haemoglobin, g/dL 10.7± 1.4 10.3± 1.4 10.8±1.3 11.2±1.3* <0.001
Platelets, ×104/𝜇L 16.4± 10.1 16.8± 13.4 16.7± 5.8 15.8± 6.1 0.72
Reticulocyte, % 1.6 (1.3–2.1) 1.5 (1.2–2.0) 1.6 (1.3–1.8) 1.7 (1.4–2.2) 0.093
RPI 0.9 (0.7–1.2) 0.8 (0.6–1.1) 0.9 (0.7–1.1) 1.1 (0.8–1.5)* <0.001
Fe, μg/dL 47.6± 30.6 45.9± 29.3 45.9± 25.6 51.5± 35.6 0.33
Ferritin, μg /L 97 (48–224) 135 (58–267) 86 (45–151) 74 (39–163) 0.52
TSAT, % 18.3± 11.8 18.4± 10.7 16.8± 9.7 19.3±14.4 0.41
Iron deficiency, n (%) 204 (65) 93 (62) 48 (68) 63 (64) 0.57
eGFR, mL/min/1.73m2 41.5 (27.7–54.7) 37.0 (25.7–53.7) 45.5 (34.5–55.6) 38.7 (27.7–56.0) 0.30
Sodium, mEq/L 139.4± 4.5 138.7± 5.4 139.9± 3.5 140.2± 3.6 0.019
BNP, pg/mL 600 (300–1066) 517 (262–930) 606 (326–935) 753 (335–1408)* 0.008
hs TnT, ng/mL 0.04 (0.03–0.07) 0.04 (0.03–0.07) 0.04 (0.02–0.06) 0.04 (0.03–0.07) 0.53
CRP, mg/dL 0.46 (0.14–1.62) 0.41 (0.10–1.71) 0.44 (0.16–1.80) 0.53 (0.21–1.50) 0.57
Renin activity, ng/mL/h 1.8 (0.7–6.4) 2.0 (0.8–6.5) 1.4 (0.4–3.4) 1.8 (0.5–9.6) 0.128
Aldosterone, ng/dL 8.5 (5.4–21.3) 8.4 (5.5–15.5) 8.0 (4.8–32.1) 9.5 (5.3–30.1) 0.166
Lactate, mg/dL 11.7 (9.0–17.0) 11.0 (8.7–15.8) 12.5 (8.8–15.1) 15.2 (9.0–19.0) 0.072
Urinary albumin, mg/g creatinine 69 (28–193) 80 (36–259) 70 (23–178) 49 (22–177) 0.191
Urine NAG, U/L 8.5 (4.8–14.0) 8.2 (4.8–13.9) 9.3 (5.3–13.7) 8.2 (4.4–14.7) 0.79
Urine 𝛽2-MG, μg/L 534 (140–2405) 649 (147–2650) 347 (127–2240) 346 (115–1630) 0.91
Intravenous treatments
Diuretics, n (%) 235 (75) 112 (76) 45 (64) 78 (80) 0.074
Vasodilators, n (%) 192 (61) 86 (59) 39 (55) 67 (68) 0.153
Inotropes, n (%) 39 (13) 15 (10) 6 (8) 18 (19) 0.081
Continuous variables are presented as mean± SD if normally distributed, and median (interquartile range) if not normally distributed.
Categorical variables are presented as number of patients (%).
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; Fe, serum iron; hs TnT, high sensitive troponin T; MG, microglobulin; NAG,
N-acetyl-𝛽-D-glucosaminidase; O/P, observed/predicted; RPI, reticulocyte production index; TSAT, transferrin saturation.
*P< 0.01 vs. lower EPO level than expected.
pathophysiological mechanisms of a high EPO level independent of
the stimulus of a lower haemoglobin level.
Several mechanisms have been hypothesized with respect
to the circulating high EPO level in high-risk HF patients.9–12
First, in HF, enhanced EPO production in the kidney may be a
response to renal hypoxia due to reduced renal perfusion caused
by decreased cardiac output, and not merely a response to a
lower haemoglobin level. In our analyses, patients with a higher
EPO level had lower blood pressure, impaired renal function,
and more frequent requirement for inotropes than those with
a lower EPO level; nevertheless, haemoglobin level rather than
eGFR and iron status (Fe, ferritin, and TSAT) was the strongest
independent determinant of EPO levels, and SpO2 level tended
to be decreased in anaemic patients with a higher than expected
EPO level. Thus our results indicate that anaemia and hypoxia
rather than renal perfusion might synergistically stimulate EPO
production. Secondly, the renin–angiotensin–aldosterone sys-
tem, which is often activated in HF, is known to enhance EPO
production;11 however, our study demonstrated that neither the .
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.. systemic renin activity nor the aldosterone level was positively
correlated with the EPO level. Thirdly, an altered metabolic state,
causing the oxygen–haemoglobin dissociation curve to shift to the
right, may influence EPO production, as previously suggested.10
Fourthly, the active proinflammatory state in ADHF may cause an
insufficient response of bone marrow to stimulation by EPO.9,12
Contrary to this hypothesis, RPI was higher in our anaemic
patients with a higher than expected EPO level compared with
those with a lower than expected EPO level. Therefore, it might
be difficult to explain a high EPO level by blunted bone marrow
responsiveness to EPO stimulation. Fifthly, in our study, because
the estimated PV excess rate was positively correlated with log
EPO level in total patients, and anaemic patients with a higher
than expected EPO level tended to show a higher estimated
PV excess rate, severe congestion with hypoxia and a higher
plasma lactate level in the acute decompensated phase might
contribute to the elevated circulating EPO level. Taking all these
findings together, anaemia and hypoxia due to severe congestive
status, rather than decreased renal perfusion and bone marrow
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Figure 3 Kaplan–Meier analyses of clinical outcomes categorized by expected erythropoietin (EPO) level in the anaemic subgroup. (A)
Composite of all-cause death and worsening heart failure. (B) All-cause death. (C) Worsening heart failure.
hyporesponsiveness to EPO stimulation, may cause circulating
high EPO levels in the decompensated phase in high-risk ADHF
patients.
Despite the fact that previous experimental studies have demon-
strated that EPO ameliorates LV dysfunction by enhancing neovas-
cularization and preventing apoptosis, major randomized clinical
trials in HF patients with anaemia failed to demonstrate efficacy
on clinical outcomes;23–26 in contrast, concern about increased
thrombotic complications was raised.27,28 Indeed, high EPO levels
have been reported to be associated with stroke in the general
female population, possibly due to thrombogenicity and endothelial
damage.29 Nevertheless, in the present study, we found no signif-
icant association of markers of thrombogenicity (platelet count)
and endothelial damage (urinary albumin level) with EPO level and
clinical outcome. These results and our present findings suggest .
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. that circulating high EPO levels in high-risk HF patients may act as
a surrogate marker rather than a therapeutic target.
Limitations
First of all, although the study population was relatively large
compared with those of previous studies examining the clini-
cal implication of EPO measurement, the present sample size,
especially the anaemic subgroup, was still small, thereby limiting
the ability to generalize the findings and the statistical power
for detecting differences in negative data. Therefore, further
prospective studies with a larger population are warranted. Sec-
ondly, several parameters other than RPI that can evaluate bone
marrow responsiveness to EPO stimulation, such as reticulocyte
haemoglobin content, immature reticulocyte fraction, and soluble
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Table 7 Cox proportional hazards model for composite of death and worsening heart failure in the anaemic
population
Univariate Multivariate
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Variable HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Higher than expected EPO level 1.59 (1.08–2.31) 0.021 1.63 (1.05–2.49) 0.028
Age, 5 years 1.02 (0.93–1.13) 0.64 Not selected –
Systolic BP, 10mmHg 0.89 (0.83–0.95) <0.001 0.92 (0.85–0.98) 0.015
BNP, 100 pg/mL 1.04 (1.01–1.06) 0.005 1.03 (1.00–1.06) 0.020
eGFR, 10mL/min/1.73m2 0.84 (0.75–0.93) <0.001 0.91 (0.82–1.02) 0.107
Haemoglobin, 1 g/dL 0.88 (0.77–1.00) 0.042 0.85 (0.74–0.98) 0.025
SpO2, 1% 0.98 (0.95–1.02) 0.32 Not selected –
Sodium, 1mEq/L 0.94 (0.91–0.98) 0.004 0.95 (0.92–0.99) 0.017
Urinary albumin, 100mg/g creatinine 1.01 (0.99–1.03) 0.26 Not selected –
Platelets, 104/𝜇L 0.97 (0.94–1.01) 0.18 Not selected –
Male 1.12 (0.76–1.66) 0.57 Not selected –
Lactate, 1mg/dL 1.00 (0.95–1.03) 0.80 Not selected –
Estimated PV excess rate, 1% 0.99 (0.97–1.00) 0.13 Not selected –
BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; EPO, erythropoietin; HR, hazard ratio; PV, plasma volume; SpO2, oxygen saturation by
pulse oximetry.
transferrin receptor, were not measured in our study. Finally, the
true aetiology of anaemia was not confirmed in this observational
study.
Conclusion
A high EPO level during the decompensated phase was inde-
pendently related to worse clinical outcomes in ADHF patients.
Anaemia and hypoxia due to severe congestion might cause a high
EPO level, thereby strengthening its prognostic significance.
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